Cargando…

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556

Detalles Bibliográficos
Autores principales:	van Baar, Michaël J.B., van Ruiten, Charlotte C., Muskiet, Marcel H.A., van Bloemendaal, Liselotte, IJzerman, Richard G., van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2019
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754234/ https://www.ncbi.nlm.nih.gov/pubmed/31431451 http://dx.doi.org/10.2337/dc19-er10a

Ejemplares similares

Erratum. Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care 2018;41:2361–2369
por: Vaisar, Tomas, et al.
Publicado: (2019)

Erratum. Increased Prevalence of Type 2 Diabetes–Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait. Diabetes Care 2018;41:2595—2602
por: Skinner, Sarah C., et al.
Publicado: (2019)

Erratum. The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future. Diabetes Care 2018;41:209–218
por: Siminerio, Linda M., et al.
Publicado: (2018)

Erratum. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590–1599
por: LeBlanc, Erin S., et al.
Publicado: (2019)

Erratum. Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective. Diabetes Care 2018;41:1125–1131
por: Beran, David, et al.
Publicado: (2018)

Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41:1672–1680
por: Ritzel, Robert, et al.
Publicado: (2019)

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
por: van Ruiten, Charlotte C, et al.
Publicado: (2022)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Erratum. Elevated Serum Xanthine Oxidase Activity Is Associated With the Development of Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care 2018;41;884–890
por: Li, Xue, et al.
Publicado: (2019)

Erratum. Functional Brain Networks Are Altered in Type 2 Diabetes and Prediabetes: Signs for Compensation of Cognitive Decrements? The Maastricht Study. Diabetes 2016;65:2404–2413
por: van Bussel, Frank C.G., et al.
Publicado: (2017)

Alterations in white matter volume and integrity in obesity and type 2 diabetes
por: van Bloemendaal, Liselotte, et al.
Publicado: (2016)

Gut Microbiota Metabolites of Dietary Lignans and Risk of Type 2 Diabetes: A Prospective Investigation in Two Cohorts of U.S. Women. Diabetes Care 2014;37:1287–1295
por: Sun, Qi, et al.
Publicado: (2014)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Erratum. Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes. Diabetes 2013;62:3224–3231
por: Weil, E. Jennifer, et al.
Publicado: (2018)

Erratum. Dietary Protein Intake and Incidence of Type 2 Diabetes in Europe: The EPIC-InterAct Case-Cohort Study. Diabetes Care 2014;37:1854–1862
por: van Nielen, Monique, et al.
Publicado: (2015)

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2021)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232
por: Vora, J
Publicado: (2013)

Response to Comment on Lacy et al. Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. Diabetes Care 2018;41:2339–2345
por: Lacy, Mary E., et al.
Publicado: (2019)

Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97
por: Hampp, Christian, et al.
Publicado: (2020)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Response to Comment on Mulukutla et al. Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of “A+” Subtypes of Ketosis-Prone Diabetes. Diabetes Care 2018;41:2637–2640
por: Mulukutla, Surya N., et al.
Publicado: (2019)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
por: Kazda, Christof M., et al.
Publicado: (2017)

Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581–1583
Publicado: (2013)

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Erratum. Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts. Diabetes 2018;67:507–517
por: Gu, Junlian, et al.
Publicado: (2020)

Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care 2021;44:1062–1069
por: Ahuja, Vasudha, et al.
Publicado: (2021)

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
por: Ferrannini, Ele, et al.
Publicado: (2021)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Erratum. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14–19
por: Salas-Salvadó, Jordi, et al.
Publicado: (2018)

Erratum. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733–1738
por: Buckley, Leo F., et al.
Publicado: (2018)

Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418
por: Solomon, Sharon D., et al.
Publicado: (2017)

Erratum. DDB1-Mediated CRY1 Degradation Promotes FOXO1-Driven Gluconeogenesis in Liver. Diabetes 2017;66:2571–2582
por: Tong, Xin, et al.
Publicado: (2017)

Response to Comment on Chan et al. FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes. Diabetes Care 2018;41:178–186
por: Divers, Jasmin, et al.
Publicado: (2018)

Erratum. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016;39:808–815
por: Steven, Sarah, et al.
Publicado: (2018)

Erratum. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A(1c) Testing. Diabetes Care 2019;42:576–584
por: Evron, Joshua M., et al.
Publicado: (2020)

Erratum. Time Trends of Dietary and Lifestyle Factors and Their Potential Impact on Diabetes Burden in China. Diabetes Care 2017;40:1685–1694
por: Li, Yanping, et al.
Publicado: (2018)

Erratum. Relations Between Subclinical Disease Markers and Type 2 Diabetes, Metabolic Syndrome, and Incident Cardiovascular Disease: The Jackson Heart Study. Diabetes Care 2015;38:1082–1088
por: Xanthakis, Vanessa, et al.
Publicado: (2021)

Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k8g2g2q3har3q7k92rrm7pdept